The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
MoneyWeek podcast
Biotech stocks

The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers

The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think t…
3 Dec 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Woman getting an injection
Biotech stocks

Big Pharma deserves its reward for coming up with Covid-19 vaccines

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
Scientist doing science things
Biotech stocks

More good news as AstraZeneca finds a third Covid vaccine

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
People

Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine

Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…
21 Nov 2020
Moderna’s “stunning” second vaccine
Scientist doing science
Biotech stocks

Moderna’s “stunning” second vaccine

America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
19 Nov 2020
Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?
Biotech stocks

Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?

A vaccine that appears so far to be safe and effective is making its way through the final trials before commercialisation. There are reasons to be ch…
12 Nov 2020
Novo Nordisk: Denmark’s dominant drug maker
Share tips

Novo Nordisk: Denmark’s dominant drug maker

Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.
4 Nov 2020
Cover of MoneyWeek magazine issue no 1022, Friday 23 October 2020

Subscribe to MoneyWeek and get your first six issues FREE

Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
How to profit from the development of new auto-immune disease drugs
Biotech stocks

How to profit from the development of new auto-immune disease drugs

Some debilitating conditions are caused by the body’s defence mechanism going awry. Dr Mike Tubbs appraises a key subsector of the pharmaceuticals mar…
29 Oct 2020
Cash injection: join the hunt for a coronavirus vaccine
Biotech stocks

Cash injection: join the hunt for a coronavirus vaccine

Covid-19 has renewed interest in preventing the spread of viruses. But the appeal of this rapidly growing sub-sector of the pharmaceuticals market sho…
29 Oct 2020
The MoneyWeek Podcast: the accelerating revolution in healthcare
Biotech stocks

The MoneyWeek Podcast: the accelerating revolution in healthcare

Merryn talks to Dr Paul Jordan, Anna Macdonald, and Dr Gareth Blades of Amati Global investors about some of their favourite small UK companies - incl…
1 Oct 2020
The race for a coronavirus vaccine heats up
Biotech stocks

The race for a coronavirus vaccine heats up

Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.
28 Aug 2020
Profit from the fast growth of the haircare industry
Share tips

Profit from the fast growth of the haircare industry

Our society has become much more image-conscious, while new consumers worldwide want to look good too. From shampoos to new potential cures for baldne…
6 Aug 2020
Which Covid-19 vaccines look likely to be the best bets?
Biotech stocks

Which Covid-19 vaccines look likely to be the best bets?

The race to produce a treatment to prevent Covid-19 has hundreds of entrants. How should investors approach it? Matthew Partridge reports.
24 Jul 2020
Syncona: a biotech trust that's going for a song
Investment trusts

Syncona: a biotech trust that's going for a song

Syncona is an investment trust that invests in promising, privately-held biotechnology companies. It looks too cheap.
15 Jun 2020
AstraZeneca mulls €240bn mega-merger with Gilead Sciences
Stockmarkets

AstraZeneca mulls €240bn mega-merger with Gilead Sciences

Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.
11 Jun 2020
Compound interest: the eighth wonder of the world
Funds

Compound interest: the eighth wonder of the world

Setting up a pharmaceuticals trust in the mid-1990s taught Max King the power of compounding
26 May 2020
The race to defeat the superbugs has just begun
Biotech stocks

The race to defeat the superbugs has just begun

Drug-resistant bacteria are far more dangerous than Covid-19. So will we soon see major progress in developing new antibiotics? It will be a long slog…
22 May 2020
Biotech firm's shares soar on hopes of a Covid-19 vaccine
US stockmarkets

Biotech firm's shares soar on hopes of a Covid-19 vaccine

Shares in biotech firm Moderna have rocketed after an early-stage trial of a drug showed promise. But they could soon return to earth. Matthew Partrid…
21 May 2020
Look beyond Merck’s miracle cancer drug for profits
Share tips

Look beyond Merck’s miracle cancer drug for profits

Keytruda, Merk’s cancer treatment, is a winner. But it’s not the only reason to be bullish on the pharma group.
18 May 2020
Three stocks to profit from the healthcare innovation revolution
Share tips

Three stocks to profit from the healthcare innovation revolution

Anthony Ginsberg, manager of the HAN-GINS Indxx Healthcare Innovation UCITS ETF, picks three of his favourite healthcare stocks to buy now.
11 May 2020
Three biotech stocks to buy for healthy long-term returns
Share tips

Three biotech stocks to buy for healthy long-term returns

Professional investor Marek Poszepczynki of the International Biotechnology Trust picks three biotech stocks with strong balance sheets that look well…
27 Apr 2020
Gilead's anti-viral expertise will stand it well
Share tips

Gilead's anti-viral expertise will stand it well

There is far more to biotech giant Gilead Sciences than its potential treatment for Covid-19; it has expertise in anti-virals against a wide range of …
14 Apr 2020